Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery

Completed

Conditions studied: Breast Cancer

In brief

Conventional mammography is not a reliable method for determining the extent of disease in women with breast cancer. Molecular Breast Imaging (MBI) is a new nuclear medicine technique that allows the breast to be imaged in a manner similar to mammography, but without the pain of compression. Initial results with this method have shown it is very good at detecting small breast cancers (\~1/4 inch). The purpose of this study is to see if MBI is a better method than mammography in determining how much cancer is present before a woman goes to surgery. The study will comprise 120 women with breast cancer who are going to surgery. The investigators hope that this study will demonstrate that MBI will be more accurate in determining how much cancer is present.

Key facts

Study ID

NCT00776308

Run by

Mayo Clinic

People needed

98

Starts

2008-10-01

Expected to finish

2011-02-01

Last updated by the study team

2012-01-25

Who can join

Age: 25 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women with biopsy-proven breast cancer (invasive breast cancer or ductal carcinoma in situ)

You may not qualify if…

• Unable to understand and sign the consent form
• Pregnant or lactating
• Physically unable to sit upright and still for 40 minutes
• Currently receiving neoadjuvant chemotherapy or hormonal therapy
• Currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor
• Previous mastectomy
• Previous excisional biopsy of the index breast cancer

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.